Brian Lortie

Brian Lortie has an extensive work experience in the pharmaceutical industry. Brian is currently the Chief Executive Officer at Nexstone Immunology since January 2022.

Prior to this, Brian served as the President and CEO of Onspira Therapeutics, Inc. from January 2017 to December 2019. At Onspira, they focused on the development of life-changing medicines for patients suffering from rare pulmonary diseases, specifically bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients.

From May 2014 to October 2016, Brian worked at Endo Pharmaceuticals as the President, Branded Pharmaceuticals. Brian had complete P&L and operating responsibility for the Branded Pharmaceutical business. Brian was a key member of the corporate Executive Leadership Team. Before this role, they served as the Senior Vice-President and General Manager, Branded Pharmaceuticals from February 2011 to May 2014, and as the Senior Vice-President - Endo Pain Solutions from July 2009 to February 2011.

Brian also had a significant tenure at GlaxoSmithKline. From January 2008 to June 2009, they were the VP of Venture Development. Brian previously held positions such as VP and Global Head, HPV Vaccine Development, VP Marketing and Business Unit Head, Regional VP of Sales, and Managing Director and GM of Ireland.

Overall, Brian Lortie has held top executive positions in various pharmaceutical companies, demonstrating their expertise in strategic, commercial, and operational functions.

Brian Lortie completed their graduate study in business from the Villanova School of Business from 1992 to 1995. Brian focused on Business Administration and Management with a general field of study. Prior to that, from 1978 to 1982, Brian obtained their BA cum laude in Psychology and Biology from Boston University. Their earlier education includes attending The Bromfield School from 1974 to 1978, but no specific degree or field of study is mentioned for this period.